Close Menu

Memorial Sloan-Kettering

Immunotherapy Buzz

The New York Times looks at immunotherapy and its use in cancer treatment.

In a cohort of more than 150 patients, none who responded well to anti-androgen therapy had AR-V7-positive circulating tumor cells detected by Epic's technology.

The partners will focus on microbiome drugs for cancer patients undergoing hematopoietic stem cell transplantation or receiving checkpoint inhibitors.

Some 20 percent of 650 clinical germlines analyzed since the project launched last year have had at least one variant associated with increased cancer risk.

The institute will combine expertise from six cancer centers in the US in order to drive research and drug development in cancer immunotherapy. 

The data included results from thousands of clinically tested samples showing frequent identification of clinically useful diagnostic and prognostic markers.

The partners will evaluate the ability of ImmunID's ImmunTracker assay to predict the responses of patients with solid tumors to cancer immunotherapy.

Two separate studies concluded that in most SEO cancer cases what they are seeing are two separate early-stage tumors, instead of late-stage cancer.

Sage is handling the initial data processing and cleaning for the consortium, while MSKCC is providing infrastructure for hosting the data.

Researchers from Memorial Sloan Kettering found that many cancer patients harbor germline variants, sometimes in unexpected genes, that could inform their care.

Pages

A South African university has told the Wellcome Sanger Institute to return DNA samples it has from indigenous African communities, The Times reports.

The University of California, Berkeley's Rasmus Nielsen and Xinzhu Wei have retracted their CCR5 gene paper due to a technical artifact.

 

University of Virginia researchers are exploring a genetic risk test to gauge type 1 diabetes risk, NPR reports.

In PNAS this week: researchers compare two high-grade neuroendocrine lung cancers, height among ancient Europeans, and more.